Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
This review (2014) examines the commonalities and differences across hallucinations occurring in schizophrenia and in response to psychostimulants, psychedelics, and dissociative anesthetics. They identify three principal pharmacological mechanisms activation of dopamine D2 receptors (D2Rs) with psychostimulants, (2) activation of serotonin 5HT2A receptors (HT2ARs) with psychedelics, and (3) blockage of glutamate NMDA receptors (NMDARs) with dissociative anesthetics, each of which explains different aspects of clinically observed hallucinations amongst patients with schizophrenia.
Authors
- Rolland, B.
- Jardri, R.
- Amad, A.
Published
Abstract
Introduction
Hallucinations are complex misperceptions, that principally occur in schizophrenia or after intoxication induced by three main classes of drugs: psychostimulants, psychedelics, and dissociative anesthetics. There are at least three different pharmacological ways to induce hallucinations: (1) activation of dopamine D2 receptors (D2Rs) with psychostimulants, (2) activation of serotonin 5HT2A receptors (HT2ARs) with psychedelics, and (3) blockage of glutamate NMDA receptors (NMDARs) with dissociative anesthetics. In schizophrenia, the relative importance of NMDAR and D2R in the occurrence of hallucinations is still debated. Slight clinical differences are observed for each etiology.Methods/Results: Thus, we investigated whether the concept of hallucination is homogenous, both clinically and neurobiologically. A narrative review of the literature is proposed to synthesize how the main contributors in the field have approached and tried to solve these outstanding questions. While some authors prefer one explanatory mechanism, others have proposed more integrated theories based on the different pharmacological psychosis models. In this review, such theories are discussed and faced with the clinical data. In addition, the nosological aspects of hallucinations and psychosis are addressed.
Discussion
We suggest that if there may be common neurobiological pathways between the different pharmacological systems that are responsible for the hallucinations, there may also be unique properties of each system, which explains the clinical differences observed.
Research Summary of 'Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?'
Introduction
Hallucinations are defined as perceptions in the absence of an external stimulus and occur across a range of psychiatric and neurological states, most characteristically in schizophrenia. Rolland and colleagues note that hallucinations may also be pharmacologically induced by three broad drug classes: psychostimulants (e.g. cocaine, amphetamine), dissociative anaesthetics (e.g. PCP, ketamine) and classical psychedelics (e.g. LSD, psilocybin). Each class maps onto a different principal receptor mechanism—dopamine D2 receptor (D2R) hyperactivation for psychostimulants, NMDA receptor (NMDAR) blockade for dissociative anaesthetics, and 5HT2A receptor (5HT2AR) stimulation for psychedelics—which raises the question whether the clinical and neurobiological phenomenon called “hallucination” is homogeneous or instead comprises distinct forms with different substrates. This paper presents a narrative synthesis of the literature addressing those competing and complementary models. Rolland and colleagues set out to summarise the three pharmacological models, examine pairwise and fully integrated interactions among D2Rs, NMDARs and 5HT2ARs, and confront these mechanistic accounts with clinical phenomenology and neuroimaging findings. The aim is to evaluate whether a unified circuit-level explanation can accommodate observed clinical differences or whether each receptor system confers a characteristic hallucinatory profile.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topics
- APA Citation
Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. (2014). Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?. BioMed Research International, 2014, 1-9. https://doi.org/10.1155/2014/307106
References (9)
Papers cited by this study that are also in Blossom
Winter, J. C. · Psychopharmacology (2008)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
González-Maeso, J., Sealfon, S. C. · Trends in Neuroscience (2009)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Cited By (5)
Papers in Blossom that reference this study
Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.